Senology.org - Newsletter

International Senologic and Oncologic  Scientific Community (ISOSC) 

"Connecting specialists worldwide"

 Editor-in-Chief: Gian Paolo Andreoletti, MD

Subscribe       Unsubscribe       Contact       Back Issues     

 

Connecting Specialists Worldwide

Join us on  LinkedIn, Twitter, Facebook, ResearchGate, Doctorsbook, Google Groups, YouTube, SlideShare, Flickr, and share informations and opinions. Check out Senology.org Newspaper and follow our RSS feeds for real-time updates

 

Literature Selection

Comment

  • "The European breast screening programmes are preventing large numbers of breast cancer deaths" , Mireille Broeders, Department of Epidemiology, Biostatistics and HTA, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
     
    "After considering all published data from European studies, the reduction in breast cancer mortality associated with mammographic population-based service screening programmes is in the range of 25–31% for women invited for screening and 38–48% for women actually screened with  sufficient follow-up time. It appears that much of the current controversy surrounding the value of mammography screening is due to the use of inappropriate methodological approaches that are unable to capture the true effect of mammographic screening. Overall, the results of this first comprehensive review of European breast screening services show that for every 1,000 women screened every two years from the age of 50 to the age of about 68-69, between seven and nine lives would be saved, and four cases would be over-diagnosed. The European breast screening programmes are preventing large numbers of breast cancer deaths, and the benefits outweigh the harms of screening. The programmes should continue to provide high quality screening services and should work towards achieving targets on coverage, uptake and assessment rates. In addition, communication methods should be improved in order to raise women’s awareness, and to make information on the pros and cons of breast cancer screening more accessible, relevant and comprehensible"
    (Commentary on:  Broeders M et al.: "The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies ", J Med Screen 2012 Sep: 19(1): 14-25)

      "Review of breast cancer screening programs in Europe: lives saved by screening outweigh over-diagnosed cases by a factor of two to one" - Share your opinion on  LinkedIn®

Calendar of Events

Literature Selection

Fragments of History

  • 1914 - Proposal by Theodor Boveri (Bamberg, 1862 - Wurzburg, 1915) that cancer can be triggered by chromosomal mutations

Literature Selection

 

Senology.org collaborates with TalkAboutHealth.com - "Cancer questions, answers, and support". Follow the Expert Q&A Workshops and join the conversation.

Q&A of the month 

"Currently the only targeted therapy routinely employed in ovarian cancer is directed at the cancer-associated blood vessels. The term, “anti-angiogenesis”, is employed to describe this therapeutic concept. The drug, bevacizumab, has been shown to be helpful in some patients when used alone (single agent therapy) or employed in combination with certain chemotherapeutic agents. Other targeted therapies remain under active clinical investigation (for example, PARP inhibitors), but have not at this point in time been approved for routine use by the FDA outside the confines of clinical trials" 
(Answer by Maurie Markman,  Cancer Treatment Centers of America, USA)

 

Stay informed....

Recent Advances in Clinical Medicine

 

Unsubscribe

     

www.senology.org